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Abstract
Background This multicenter, randomized phase II trial
was conducted to compare the efficacy and safety of
nimotuzumab plus irinotecan (N-IRI) versus irinotecan
alone (IRI) in patients with advanced gastric cancer (AGC)
showing disease progression after previous 5-fluorouracil-
based therapy.
Methods Irinotecan-naive patients (n = 82) received
N-IRI (nimotuzumab 400 mg weekly plus irinotecan
150 mg/m2 biweekly) or IRI (irinotecan 150 mg/m2
biweekly) until disease progression. The primary endpoint
was progression-free survival (PFS), and the secondary
endpoints were overall survival (OS), response rate (RR),
safety, tolerability, and the correlation between efficacy
and tumor epidermal growth factor receptor (EGFR)
expression.
Results Of 83 patients, 40 and 43 patients were randomly
assigned to the N-IRI and IRI groups, respectively. In the
N-IRI/IRI treatment group, median PFS was 73.0/
85.0 days (P = 0.5668), and median OS and RR at
18 months were 250.5/232.0 days (P = 0.9778) and 18.4/
10.3 %, respectively. Median PFS and OS in the EGFR
2?/3? subgroups were 118.5/59.0 and 358.5/229.5 days,
respectively. The RR was 33.3/0.0 % in the N-IRI/IRI
treatment group. The incidence of grade 3 or higher
adverse events was 77.5/64.3 %. No adverse events of
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grade 3 or higher skin rash or grade 3 or higher infusion-
related reaction were reported.
Conclusions There was no superiority of N-IRI over IRI
alone in terms of PFS in 5-fluorouracil-refractory AGC
patients. However, N-IRI showed potential improvement in
the EGFR 2?/3? subgroup based on improved RR, PFS,
and OS.
Keywords Nimotuzumab  Anti-EGFR  Irinotecan 
Second-line therapy  Advanced gastric cancer
Introduction
Patients with unresectable gastric cancer receiving the best
supportive care have poor outcomes, with median survival
times ranging from 3 to 5 months [1, 2]. In the metastatic
disease setting, palliative chemotherapy improves survival
compared with supportive care alone, with combined drug
therapy yielding the best results [1–3]. Although there is no
universally accepted standard treatment for advanced gas-
tric cancer (AGC), several combination regimens have
been used as first-line treatment, including epirubicin–ox-
aliplatin–capecitabine [4], cisplatin–capecitabine [5], cis-
platin-S-1 [6], cisplatin–5-fluorouracil, and docetaxel–
cisplatin–5-fluorouracil [7]. However, the median survival
has not exceeded 8–13 months [1–7], and second-line
treatments need to be established. Irinotecan [8, 9] or
paclitaxel monotherapy is commonly used for AGC
patients as second-line treatment, especially in Japan and
Korea. Because of the limitations of the current therapies,
addition of molecular-targeted drugs, particularly to
chemotherapies with acceptable toxicities, may improve
the outcomes. The ToGA trial demonstrated that the
addition of trastuzumab to standard chemotherapy in
patients with human EGFR-2 (HER-2)-overexpressing
tumors improved overall survival (OS) and progression-
free survival (PFS) [10].
Epidermal growth factor receptor (EGFR) is known to
be expressed in a variety of tumors [11]. Approximately
30 % of gastric cancers are reported to show EGFR over-
expression [12, 13]. EGFR signaling pathways are fre-
quently dysregulated in gastric cancer, thereby serving as
attractive therapeutic targets.
Nimotuzumab, a recombinant humanized monoclonal
immunoglobulin G1 antibody against human EGFR (HER-
1), blocks the binding of epidermal growth factor (EGF) and
transforming growth factor-a to EGFR. This mechanism
regulates antibody-dependent cellular cytotoxicity and
complement-dependent cytotoxicity, inhibiting tumor cell
growth and angiogenesis and inducing apoptosis [14–17]. In
a previous phase I study in Japan, the safety and tolerability
of nimotuzumab were investigated up to 400 mg doses
weekly [18]. When combined with radiotherapy or che-
moradiotherapy, nimotuzumab exerts clinical efficacy
against head and neck cancers, gliomas, and non-small cell
lung cancer (NSCLC) [17, 19, 20]. Additionally, because of
the low frequency of severe dermatological toxicity, nim-
otuzumab is expected to improve the quality of life.
The present study was an open-label, phase II collabo-
rative study between Japan and Korea. The primary
objective was to compare PFS following combined nim-
otuzumab plus irinotecan therapy (N-IRI) and irinotecan
monotherapy (IRI) in patients with unresectable or recur-
rent gastric cancer refractory to 5-fluorouracil-based
therapy.
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Materials and methods
Patients
Patients in Japan and Korea were enrolled in this multi-
center, open-label, randomized phase II trial. Patients with
histologically confirmed AGC refractory to previous
5-fluorouracil-based chemotherapy for metastatic disease
were eligible. Other major inclusion criteria were as fol-
lows: age of 20–75 years; adequate organ function; and
Eastern Cooperative Oncology Group performance status
(ECOG PS) 0 or 1. Major exclusion criteria were prior
exposure to irinotecan or EGFR-directed therapy, and
significant comorbidities, such as diarrhea, interstitial
pneumonia, or pulmonary fibrosis.
The trial was conducted in accordance with the Decla-
ration of Helsinki. All the patients provided written
informed consent. The institutional review boards or ethics
committees of all participating centers reviewed and
approved the protocol.
Study treatment
Patients were randomly assigned at a ratio of 1:1 to the
N-IRI or IRI group by a computer program on the basis
of the resection status of the primary tumor (inoperable
advanced/postoperative recurrent) and study site, using
the random permuted blocks method. Neither the patients
nor the investigators were blinded to the treatment
assignment.
Nimotuzumab (400 mg) diluted in normal saline to a
total volume of 250 ml was administered once weekly by
intravenous infusion over 30 min. Irinotecan (150 mg/m2)
was administered every 2 weeks. Treatment was continued
until disease progression, appearance of unacceptable
toxicity, or withdrawal of consent.
Efficacy and safety assessments
The primary endpoint was PFS following N-IRI versus IRI
treatment. PFS was defined as the time from randomization
to the day of documentation of progression or death,
whichever was earlier. The secondary endpoints were OS,
response rate (RR), disease control rate (DCR), safety, and
tolerability. Tumor assessment by computed tomography
was performed at baseline, and then every 4 weeks for the
first 16 weeks, and every 6 weeks thereafter. Evaluation of
tumors was performed by an independent Efficacy Evalu-
ation Committee using RECIST 1.0. Adverse events were
assessed according to the National Cancer Institute’s
Common Terminology Criteria for Adverse Events, ver-
sion 3.0.
Exploratory biomarker analysis
EGFR protein expression levels, EGFR gene amplification
status, K-ras mutations, and HER-2 protein expression
levels were measured in tissue specimens from tumors
obtained from patients who had provided informed consent
for exploratory biomarker analysis. The tumor tissues were
centrally tested and classified. EGFR expression was ana-
lyzed using an immunohistochemistry (IHC) staining kit
(EGFR PharmDX; Dako, Copenhagen, Denmark) and
classified into four categories (0, 1?, 2?, and 3?), as
previously described [21]. The EGFR gene copy number
was measured by fluorescence in situ hybridization (FISH),
as reported previously [22]. For K-ras mutation analysis,
DNA was extracted from formalin-fixed paraffin-embed-
ded tumor samples. The sequences of K-ras codons 12 and
13 and the surrounding region of the gene were analyzed
by conventional polymerase chain reaction followed by
direct sequencing. The expression status of HER-2 was
analyzed using the HercepTest kit (Dako) and classified
into four categories (0, 1?, 2?, and 3?).
Statistical analysis
The reported median PFS in AGC patients treated with
irinotecan or paclitaxel as second-line chemotherapy is
2.1–2.6 months [23–25]. For an exploratory study, if the
median PFS times for N-IRI and IRI therapy are assumed
to be 4.5 and 2.5 months, respectively, then 32 patients per
treatment arm would be required to detect a difference with
80 % power at a 10 % significance level using a one-sided
log-rank test of the equality of survival curves. Assuming a
dropout rate of 20 %, the number of patients per treatment
group was set at 40, with a total sample size of at least 80
patients. The median PFS was calculated with the 95 %
confidence interval (CI) for both treatment groups. Log-
rank tests were performed to evaluate differences in PFS
with the significance level set at 10 % (one sided). Primary
statistical analysis of the efficacy endpoint was performed
6 months after registration of the last patient for the study.
For subgroup analyses of PFS and OS, the hazard ratio
(HR) and 95 % CI within each subgroup were displayed in
forest plots. In both treatment groups, the Kaplan–Meier
method was used to plot the survival curves and estimate
the cumulative incidence from the day of registration to
death, as well as the cumulative incidence to disease pro-
gression. For evaluation of efficacy, point estimates were
calculated for the RR and DCR and compared using the
chi-squared test. Efficacy endpoints were analyzed using
the full analysis set, safety endpoints were analyzed using
the safety analysis set, and pharmacokinetic analyses were
performed using the pharmacokinetic analysis set.
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Results
Patients
A total of 83 patients were randomized from September
2008 to December 2009. Of these patients, 82 were
included in the safety and efficacy analysis population (1
patient from the IRI group did not have a target lesion and
did not receive irinotecan; Fig. 1). At the 18-month follow-
up after registration of the last patient for the study, the
median nimotuzumab and irinotecan exposure in the N-IRI
group was 71.5 days (range, 8–947) and 60.5 days (range,
1–268), respectively, and the median irinotecan exposure
in the IRI group was 57.0 days (range, 1–953). The median
follow-up period was 242.5 days (range, 22–955). Patient
demographics, including the UGT1A1 subtype, were well
matched between the two treatment groups (Table 1).
Of the 83 patients, 48 patients had provided informed
consent for exploratory biomarker analysis and submitted
tumor samples. The EGFR protein expression level was
detected in the assessable tumor tissues of 47 patients
(57.3 % of the full analysis set population) (Table 2).
Efficacy
A total of 77 patients (n = 38 in the N-IRI group and
n = 39 in the IRI group) were evaluable for radiologic
tumor responses by an Independent Efficacy Evaluation
Committee. PFS evaluated at 6 months after registration of
the last patient was not significantly different between the
treatment groups [median (95 % CI), 73.0 (55.0–112.0)
days in the N-IRI group vs. 85.0 (37.0–93.0) days in the IRI
group; HR (95 % CI), 0.860 (0.516–1.435), P = 0.5668]
(Fig. 2).
By 18 months after registration of the last patient, 34
patients from each group had died and the 18-month OS
was not significantly different between the treatment
groups [median (95 % CI), 250.5 (171.0–306.0) days in the
N-IRI group vs. 232.0 (148.0–319.0) days in the IRI group;
HR (95 % CI), 0.994 (0.618–1.599), P = 0.9778]. There
N-IRI arm
(n = 40)
IRI arm
(n = 42)
Nimotuzumab plus irinotecan
(N-IRI arm)
(n = 40)
Randomly assigned
(n = 83)
Irinotecan
(IRI arm)
(n = 43)
Did not receive irinotecan
(n = 1)
Full analysis 
set
population
Fig. 1 CONSORT diagram. N-IRI nimotuzumab plus irinotecan, IRI
irinotecan alone
Table 1 Baseline characteristics of the patients
Characteristics N-IRI
arm
(n = 40)
IRI arm
(n = 42)
Total
(n = 82)
n % n % n %
Age (years)
Median 60.0 63.5 61.5
Range 27–75 32–75 27–75
Sex
Male 33 82.5 33 78.6 66 80.5
Female 7 17.5 9 21.4 16 19.5
ECOG performance status
0 19 47.5 17 40.5 36 43.9
1 21 52.5 25 59.5 46 56.1
Body weight (kg)
Median 56.3 54.2 56.0
Range 42.0–81.4 37.5–107.0 37.5–107.0
Resection status of the primary tumor
Inoperable advanced 22 55.0 23 54.8 45 54.9
Postoperative recurrent 18 45.0 19 45.2 37 45.1
Histological diagnosis, n
Well/moderately
differentiated
adenocarcinoma
15 37.5 19 45.2 34 41.5
Poorly differentiated
adenocarcinoma
21 52.5 17 40.5 38 46.3
Others 4 10.0 6 14.3 10 12.2
Primary tumor site
Absent 18 45.0 16 38.1 34 41.5
Present 22 55.0 26 61.9 48 58.5
Gastroesophageal junction 4 18.2 1 3.8 5 10.4
Gastric region 18 81.8 25 96.2 43 89.6
Metastatic focus site
No 1 2.5 0 0.0 1 1.2
Yes 39 97.5 42 100.0 81 98.8
Lymph node 25 64.1 25 59.5 50 61.7
Liver 13 33.3 19 45.2 32 39.5
Lung 3 7.7 6 14.3 9 11.1
Other 19 48.7 18 42.9 37 45.7
UGT1A1 gene polymorphism
*1/*1, *1/*6, *1/*28 38 95.0 39 92.9 77 93.9
*6/*6, *28/*28, *6/*28 2 5.0 3 7.1 5 6.1
N-IRI nimotuzumab plus irinotecan, IRI irinotecan alone, n number of
patients, ECOG Eastern Cooperative Oncology Group
Nimotuzumab in gastric cancer 827
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was no significant difference in RR or DCR at the
18-month follow-up between the treatment groups (RR,
18.4 % in the N-IRI group vs. 10.3 % in the IRI group,
P = 0.3060; DCR, 47.4 % in the N-IRI group vs. 46.2 %
in the IRI group, P = 0.9150).
PFS and OS in the various subgroups analyzed were not
significantly different between the treatment groups
(Fig. 3). However, the HR (IRI/N-IRI) in the EGFR 2?/3?
subgroup was lower than that in the entire treatment group.
First, the median PFS (95 % CI) was 118.5 (87.0–not
estimated) days for six patients in the N-IRI group vs. 59.0
(24.0–113.0) days for six patients in the IRI group [HR
(95 % CI), 0.341 (0.080–1.457), P = 0.1293] (Fig. 3).
Second, the median OS (95 % CI) was 358.5 (274.0–458.0)
days for six patients in the N-IRI group vs. 229.5
(58.0–387.0) days for eight patients in the IRI group [HR
(95 % CI), 0.369 (0.110–1.242), P = 0.0944] (Fig. 3).
Furthermore, at the 18-month follow-up, the RR in the
EGFR 2?/3? subgroup was 33.3 % for six patients in the
N-IRI group vs. 0.0 % for six patients in the IRI group, and
the DCR in the corresponding groups was 83.3 % and
33.3 %, respectively.
Pharmacokinetics
Pharmacokinetic analysis was conducted using data col-
lected from 11 patients (n = 6 from the N-IRI group and
n = 5 from the IRI group). The pharmacokinetic parame-
ters of nimotuzumab were similar to those reported from a
previous phase I study of nimotuzumab in Japanese
patients with solid tumors [18].
Safety
Adverse events were reported in all the patients. Table 3
shows the incidence, by treatment group, of major adverse
events occurring at a frequency of C15 % in at least one
group. The most common adverse events (C50 % in at
least one group) were neutropenia, diarrhea, nausea, alo-
pecia, decreased appetite, fatigue, and leukopenia. A rash
occurred in 25.0 % (10/40) and 4.8 % (2/42) of patients in
the N-IRI and IRI groups, respectively. There were no
cases with severe (Cgrade 3) skin toxicity, including severe
rash. Grade 3 or higher adverse events were encountered in
77.5 % of patients in the N-IRI group and 64.3 % of
patients in the IRI group. The most common grade 3 or
higher adverse events (C10 % in at least one group) were
neutropenia, nausea, leukopenia, anemia, pneumonia, and
decreased hemoglobin. The two pneumonia-related deaths
in the N-IRI group were considered to be causally related
to the study drug. All patients with pneumonia were
evaluated by an Independent Data Monitoring Committee
to detect pneumonitis. However, no cases of pneumonitis
were identified.
The incidence of adverse events resulting in discon-
tinuation of irinotecan was 15.0 % (6/40) in the N-IRI
group and 16.7 % (7/42) in the IRI group, with no sig-
nificant difference between the two groups. The
Table 2 EGFR and HER-2 protein expression levels identified by
immunohistochemistry
EGFR
0 1? 2?, 3? Total
n % n % n % n %
HER2
0 15 31.3 8 16.7 8 16.7 31 64.6
1? 2 4.2 2 4.2 5 10.4 9 18.8
2?, 3? 4 8.3 2 4.2 1 2.1 7 14.6
Total 21 43.8 12 25.0 14 29.2 47a 97.9
EGFR epidermal growth factor receptor, n number of patients, HER2
human EGFR-2
a One sample was ‘‘not detected’’
0 28 56 84 112 140 168 196
Time (days)
a
0.00
0.25
0.50
0.75
1.00
N-IRI (n = 38)
IRI (n = 39)
No. at risk
N-IRI 38 33 23 16 10 6 2 2
IRI 39 30 17 16 8 6 3 2
N-IRI IRI
Median (days) 73.0 85.0
Hazard ratio 0.860 (0.516, 1.435) P = 0.5668
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b
0.00
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1.00
N-IRI (n = 40)
IRI (n = 42)
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Time (days)
No. at risk
N-IRI 40 33 23 16 10 5 1
IRI 42 32 25 15 9 8 1
N-IRI IRI
Median (days) 250.5 232.0
Hazard ratio 0.994 (0.618, 1.599) P = 0.9778
Fig. 2 Kaplan–Meier estimates of progression-free survival (a) and
overall survival (b). N-IRI nimotuzumab plus irinotecan, IRI irino-
tecan alone
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incidence of adverse events resulting in discontinuation
of nimotuzumab was 7.5 % (3/40) in the N-IRI treat-
ment group.
Adverse events were reported for all patients in the
EGFR 2?/3? subgroup, and no significant difference was
found in the frequency of adverse events between the IRI
Patients, n Hazard ratio [95% CI] P
Country
Japan 41 0.650 [0.320–1.323] 0.2331
Korea 36 1.262 [0.597–2.669] 0.5387
Resection status of the primary tumor
Inoperable advanced 43 1.149 [0.578–2.285] 0.6938
Post-operative recurrent 34 0.664 [0.306–1.442] 0.2996
Histological diagnosis
Well/moderately differentiated adenocarcinoma 33 0.906 [0.417–1.966] 0.8070
Poorly differentiated adenocarcinoma 35 0.860 [0.389–1.903] 0.7146
Others 9 0.637 [0.104–3.920] 0.6243
EGFR protein expression levels (IHC)
0, 1+, 2+ and 3+ 44 0.994 [0.507–1.949] 0.9798
1+, 2+ and 3+ 24 0.463 [0.177–1.212] 0.1093
2+ and 3+ 12 0.341 [0.080–1.457] 0.1293
Age
<65 45 0.848 [0.442–1.630] 0.6226
65 32 0.782 [0.328–1.862] 0.5764
Sex
Male 63 0.845 [0.482–1.482] 0.5545
Female 14 0.815 [0.232–2.868] 0.7508
ECOG PS
0 35 1.179 [0.540–2.575] 0.6786
1 42 0.692 [0.346–1.383] 0.2971
Prior platinum treatment
Yes 59 1.006 [0.559–1.810] 0.9820
No 18 0.664 [0.227–1.946] 0.4527
a
b
Favors N-IRI Favors IRI 
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
Patients, n Hazard ratio [95% CI] P
Country
Japan 42 1.013 [0.520–1.973] 0.9670
Korea 40 0.987 [0.497–1.961] 0.9690
Resection status of the primary tumor
Inoperable advanced 45 1.384 [0.752–2.548] 0.3031
Post-operative recurrent 37 0.700 [0.323–1.517] 0.3634
Histological diagnosis
Well/moderately differentiated adenocarcinoma 34 0.882 [0.400–1.945] 0.7487
Poorly differentiated adenocarcinoma 38 1.047 [0.531–2.065] 0.9044
Others 10 0.732 [0.194–2.770] 0.6449
EGFR protein expression levels (IHC)
0, 1+, 2+ and 3+ 47 1.242 [0.652–2.368] 0.5133
1+, 2+ and 3+ 26 0.549 [0.236–1.273] 0.1563
2+ and 3+ 14 0.369 [0.110–1.242] 0.0944
Age
<65 48 0.891 [0.478–1.660] 0.7155
65 34 1.091 [0.518–2.298] 0.8160
Sex
Male 66 1.086 [0.633–1.864] 0.7648
Female 16 0.997 [0.349–2.846] 0.9951
ECOG PS
0 36 1.183 [0.546–2.565] 0.6681
1 46 0.949 [0.516–1.746] 0.8653
Prior platinum treatment
Yes 63 0.929 [0.552–1.563] 0.7762
No 19 1.238 [0.377–4.066] 0.7238
Post-treatment with taxane
No 30 1.275 [0.567–2.865] 0.5557
Yes 52 1.150 [0.620–2.133] 0.6543
Taxane 35 1.313 [0.631–2.734] 0.4618
Other 17 0.853 [0.270–2.699] 0.7869
Favors N-IRI Favors IRI 
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
Fig. 3 Subset forest plots for progression-free survival (a) and overall survival (b). N-IRI nimotuzumab plus irinotecan, IRI irinotecan alone,
EGFR epidermal growth factor receptor, IHC immunohistochemistry, ECOG Eastern Cooperative Oncology Group, PS performance status
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and N-IRI groups in the EGFR 2?/3? subgroup analysis.
The incidence of adverse events in the EGFR 2?/3?
subgroup was similar to that in all randomized patients. In
the EGFR 2?/3? subgroup, rash of grade 1 or 2 occurred
in 50.0 % (3/6) and 0.0 % (0/8) of patients in the N-IRI and
IRI groups, respectively.
Discussion
The primary endpoint of prolonged PFS was not achieved
in this study, suggesting no significant benefit of N-IRI in
non-biologically selected patients with AGC. This result is
suggested by recent studies that evaluated the efficacy of
anti-EGFR antibody administration to AGC patients who
were not biologically selected. In two prospective ran-
domized phase III studies (EXPAND, REAL-3) of cetux-
imab and panitumumab conducted in AGC patients, the
primary endpoint could not be achieved [26, 27]. These
negative results emphasize the need to identify the bio-
logical target before starting a large phase III study.
In a preclinical study, nimotuzumab showed marked
antiproliferative, proapoptotic, and antiangiogenic effects
against tumors showing EGFR overexpression [14–16]. We
previously demonstrated that the effects of nimotuzumab
on human NSCLC cell lines were highly dependent on
EGFR status [28]. Nimotuzumab inhibited EGFR phos-
phorylation in cancer cells with high/moderate surface
expression of EGFR, but not in those with low surface
EGFR expression. Immunoblot analysis showed inhibition
of EGFR phosphorylation in H292 and Ma-1 cells
expressing high and moderate levels of EGFR on the cell
surface, but not in H460, H1299, and H1975 cells showing
a low level of surface EGFR expression [28].
In a clinical study of head and neck cancer to assess the
efficacy of nimotuzumab in combination with radiotherapy,
a controlled, double-blind, randomized clinical trial was
conducted. For EGFR-positive patients, a significant sur-
vival improvement was detected for nimotuzumab-treated
patients (OS, 16.5 months) compared with the control
group (OS, 7.2 months) [29].
Nimotuzumab is a humanized IgG1 antibody-directed
agent, meaning that EGFR should be considered as the first
candidate for its biological target. In this study, subset
analysis showed a median PFS of 118.5 days in the EGFR
2?/3? subgroup of the N-IRI group and 59.0 days in the
corresponding subgroup of the IRI group; the RR was
33.3 % and 0.0 %, respectively. Furthermore, there was no
significant difference in the frequency and seriousness of
adverse events between the IRI and N-IRI groups in the
subset of EGFR 2?/3? subgroup analysis. Submission of
tissue samples was not mandatory, and EGFR protein
expression was only detected for 57.3 % of the full analysis
set population. Therefore, the subset analysis based on the
EGFR status could not yield any conclusive results.
However, the results seem to imply that nimotuzumab can
improve PFS and OS in AGC patients with high EGFR
expression levels (2?/3?) when administered in combi-
nation with irinotecan.
In our study, the further exploratory biomarker of K-ras
mutations was measured in 48 patients, and only 2 patients
Table 3 Adverse events occurring at an incidence of C 15 % in each
treatment arm
Adverse event N-IRI (n = 40) IRI (n = 42)
All
grades
CGrade
3
All
grades
CGrade
3
n % n % n % n %
Infections and infestations
Pneumonia 8 20.0 4 10.0 1 2.4 0 0.0
Blood and lymphatic system disorders
Anemia 7 17.5 5 12.5 4 9.5 3 7.1
Leukopenia 20 50.0 6 15.0 15 35.7 4 9.5
Lymphopenia 7 17.5 3 7.5 4 9.5 0 0.0
Neutropenia 29 72.5 18 45.0 23 54.8 16 38.1
Thrombocytopenia 1 2.5 0 0.0 7 16.7 3 7.1
Metabolism and nutrition disorders
Hypoalbuminemia 7 17.5 0 0.0 5 11.9 1 2.4
Decreased appetite 22 55.0 3 7.5 26 61.9 3 7.1
Gastrointestinal disorders
Abdominal pain 14 35.0 0 0.0 14 33.3 3 7.1
Constipation 12 30.0 0 0.0 12 28.6 0 0.0
Diarrhea 25 62.5 3 7.5 25 59.5 2 4.8
Nausea 25 62.5 6 15.0 25 59.5 4 9.5
Stomatitis 6 15.0 0 0.0 5 11.9 0 0.0
Vomiting 17 42.5 3 7.5 13 31.0 2 4.8
Skin and subcutaneous tissue disorders
Alopecia 23 57.5 0 0.0 15 35.7 0 0.0
Rash 10 25.0 0 0.0 2 4.8 0 0.0
General disorders and administration site conditions
Asthenia 7 17.5 1 2.5 9 21.4 1 2.4
Fatigue 21 52.5 3 7.5 15 35.7 3 7.1
Pyrexia 8 20.0 0 0.0 13 31.0 0 0.0
Investigations
Alanine
aminotransferase
increased
8 20.0 1 2.5 6 14.3 1 2.4
Aspartate
aminotransferase
increased
7 17.5 1 2.5 7 16.7 1 2.4
Hemoglobin
decreased
11 27.5 4 10.0 13 31.0 6 14.3
Weight decreased 12 30.0 2 5.0 8 19.0 0 0.0
Number of patients, incidence of adverse events, and incidence of
grades 3–5 adverse events
N-IRI nimotuzumab plus irinotecan, IRI irinotecan alone, n number of
patients
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were found to harbor K-ras mutations. The EGFR gene
copy number was measured in 46 patients, and 1 patient
was detected with gene amplification. These results were
consistent with previous reports [30, 31]. The roles of K-
ras mutations and EGFR gene amplification were not clear
in this study.
Recently, the ToGA study showed that the HER-2-tar-
geting monoclonal antibody trastuzumab improved OS in
AGC patients with HER-2 protein overexpression by IHC or
gene amplification by FISH [10]. We also investigated the
HER-2 expression levels by IHC and found that 14.6 % (7/
48) of patients showed HER-2 2?/3? expression and
29.2 % (14/48) of patients showedEGFR2?/3? expression.
Only 2.1 % (1/48) of patients showed 2?/3? expression of
both EGFR and HER-2, suggesting there is little overlap
between EGFR and HER-2 overexpression in gastric cancer
[13]. Currently, targeted therapy for gastric cancer is limited
to patients with HER-2 overexpression. However, in future,
patients with gastric cancer showing EGFR overexpression
might benefit from treatment with nimotuzumab.
In the present study, rash occurred in ten patients
(25.0 %) in the N-IRI group, which represents a lower
frequency than that reported for patients receiving other
anti-EGFR monoclonal antibodies, such as cetuximab or
panitumumab [26, 27]. Furthermore, there were no cases of
severe (Cgrade 3) skin toxicity in either treatment group.
The frequency and severity of skin toxicity associated with
nimotuzumab appears to be lower than that associated with
other anti-EGFR antibodies. The safety profile of nim-
otuzumab could be expected to maintain good quality of
life as well as compliance and shows potential for combi-
nation of nimotuzumab with irinotecan. The median rela-
tive dose intensity of irinotecan and nimotuzumab was
94.94 % and 96.55 %, respectively, in the N-IRI group. In
the study of REAL-3, compliance with the baseline che-
motherapy was decreased because of some severe toxici-
ties, and the combination of a triple-chemotherapy regimen
with panitumumab appears to be difficult to deliver [27].
The mechanism underlying this lower frequency of skin
toxicity of nimotuzumab compared with that of other
known anti-EGFR antibodies has been investigated in
several recent studies [14–17, 19, 20]. These studies sug-
gested that a low incidence of skin toxicity may be asso-
ciated with the following: (1) the intermediate affinity
(Kd = 10
-8 M) of nimotuzumab, which is at least one order
of magnitude lower than that of cetuximab or panitumumab;
and (2) the different binding profile of nimotuzumab, which
requires bivalent binding for stable attachment to the cel-
lular surface compared with that of cetuximab, which
requires only monovalent binding [15, 16]. This finding
implies that nimotuzumab binding to EGFR occurs only
when the surface EGFR density is sufficiently high to allow
bivalent binding. Tumor cells overexpressing EGFR are
common, allowing for selective binding of nimotuzumab.
In conclusion, although the primary endpoint of pro-
longed PFS was not met in our study, subset analysis
showed that the N-IRI regimen may have potential to
improve PFS and OS in EGFR 2?/3? patients. An open-
label, randomized phase III trial comparing N-IRI and IRI
in EGFR 2?/3? AGC patients is currently ongoing.
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